Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 VistaGen TherapeuticsNextCureAlpine Immune SciencesiBioImmunome
SymbolNASDAQ:VTGNNASDAQ:NXTCNASDAQ:ALPNNYSEAMERICAN:IBIONASDAQ:IMNM
Price Information
Current Price$2.05$9.42$11.00$1.23$24.06
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.31.61.81.31.0
Analysis Score3.53.23.53.51.5
Community Score2.92.62.53.23.0
Dividend Score0.00.00.00.00.0
Ownership Score0.01.72.50.00.0
Earnings & Valuation Score0.00.60.60.00.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$5.67$22.55$19.40$2.50$18.00
% Upside from Price Target176.42% upside139.34% upside76.36% upside103.25% upside-25.19% downside
Trade Information
Market Cap$293.85 million$259.99 million$262.70 million$265.69 million$256.48 million
Beta0.52-0.41.72-5.81N/A
Average Volume3,405,376224,833122,66413,252,229262,474
Sales & Book Value
Annual RevenueN/A$6.35 million$1.74 million$1.64 millionN/A
Price / SalesN/A40.94150.98162.01N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.12) per share$14.13 per share$1.59 per share$0.48 per shareN/A
Price / BookN/A0.676.922.56N/A
Profitability
Net Income$-20,770,000.00$-33,740,000.00$-41,850,000.00$-16,440,000.00$-10,440,000.00
EPS($0.50)($2.15)($2.28)N/AN/A
Trailing P/E RatioN/AN/AN/A0.000.00
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-606.16%-1,005.62%N/A
Return on Equity (ROE)N/A-10.00%-80.38%-55.71%N/A
Return on Assets (ROA)-272.12%-9.51%-30.76%-26.91%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.01%0.13%0.40%N/A
Current Ratio0.82%51.73%3.98%16.84%1.38%
Quick Ratio0.82%51.73%3.98%16.67%1.38%
Ownership Information
Institutional Ownership Percentage3.13%66.30%52.86%8.78%N/A
Insider Ownership Percentage13.67%9.05%76.10%1.00%N/A
Miscellaneous
Employees1190574323
Shares Outstanding143.34 million27.60 million23.88 million216.01 million10.66 million
Next Earnings Date7/5/2021 (Estimated)5/6/2021 (Estimated)5/13/2021 (Estimated)5/21/2021 (Estimated)6/24/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Immunome Appoints Dr. Dennis Giesing as Chief Development OfficerImmunome Appoints Dr. Dennis Giesing as Chief Development Officer
finance.yahoo.com - March 30 at 9:29 AM
Immunome (NASDAQ:IMNM) Issues  Earnings Results, Misses Estimates By $0.11 EPSImmunome (NASDAQ:IMNM) Issues Earnings Results, Misses Estimates By $0.11 EPS
americanbankingnews.com - March 26 at 10:26 AM
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate UpdateImmunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
finance.yahoo.com - March 25 at 9:49 PM
Immunome, Inc.s Lock-Up Period To End  on March 31st (NASDAQ:IMNM)Immunome, Inc.'s Lock-Up Period To End on March 31st (NASDAQ:IMNM)
americanbankingnews.com - March 24 at 1:30 AM
Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling StudiesImmunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies
finance.yahoo.com - March 23 at 8:00 AM
IMNM Stock Price Increased 51.67%: Why It HappenedIMNM Stock Price Increased 51.67%: Why It Happened
pulse2.com - February 24 at 6:15 PM
Immunome shares jump on early COVID-19 antibody cocktail reportImmunome shares jump on early COVID-19 antibody cocktail report
bioworld.com - February 19 at 10:03 AM
Why Immunome Stock Skyrocketed TodayWhy Immunome Stock Skyrocketed Today
finance.yahoo.com - February 18 at 11:12 PM
Why Is It Moving? Looking Into Why Immunomes Stock is Trading Higher TodayWhy Is It Moving? Looking Into Why Immunome's Stock is Trading Higher Today
msn.com - February 18 at 1:11 PM
Immunome Shares Spike 150% Higher On Coronavirus Antibody DiscoveryImmunome Shares Spike 150% Higher On Coronavirus Antibody Discovery
msn.com - February 18 at 1:11 PM
Immunome says its antibodies may be able to neutralize Covid-19s escape mutantsImmunome says its antibodies may be able to neutralize Covid-19's 'escape mutants'
bizjournals.com - February 18 at 1:11 PM
Immunome Skyrockets on Isolation of COVID AntibodiesImmunome Skyrockets on Isolation of COVID Antibodies
msn.com - February 18 at 1:11 PM
IMNM Stock Price Increases Over 170% Pre-Market: Why It HappenedIMNM Stock Price Increases Over 170% Pre-Market: Why It Happened
pulse2.com - February 18 at 1:11 PM
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus TestingImmunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
finance.yahoo.com - February 18 at 8:11 AM
Immunome Profit Margin (Quarterly)Immunome Profit Margin (Quarterly)
ycharts.com - February 4 at 10:28 PM
Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based TreatmentAbzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment
finance.yahoo.com - February 3 at 11:25 AM
Immunomes Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 VirusImmunome's Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus
stockhouse.com - February 2 at 5:42 PM
How Much Are Immunome, Inc. (NASDAQ:IMNM) Insiders Spending On Buying Shares?How Much Are Immunome, Inc. (NASDAQ:IMNM) Insiders Spending On Buying Shares?
finance.yahoo.com - January 17 at 1:49 PM
Immunome, Inc. (IMNM)Immunome, Inc. (IMNM)
ca.finance.yahoo.com - January 9 at 12:37 AM
Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate SecImmunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Sec
us.acrofan.com - December 10 at 6:04 PM
Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate SecretaryImmunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
finance.yahoo.com - December 10 at 6:04 PM
Immunome Inc.Immunome Inc.
barrons.com - November 22 at 7:00 PM
Immunome Reports Third Quarter 2020 Financial Results and Significant ProgressImmunome Reports Third Quarter 2020 Financial Results and Significant Progress
finance.yahoo.com - November 17 at 7:08 PM
Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public OfferingImmunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
finance.yahoo.com - November 2 at 8:33 AM
DateCompanyBrokerageAction
2/25/2021VistaGen TherapeuticsJefferies Financial GroupInitiated Coverage
1/4/2021VistaGen TherapeuticsWilliam BlairUpgrade
12/22/2020VistaGen TherapeuticsMaxim GroupBoost Price Target
10/8/2020VistaGen TherapeuticsAegisInitiated Coverage
12/2/2019VistaGen TherapeuticsChardan CapitalReiterated Rating
11/4/2018VistaGen TherapeuticsOppenheimerSet Price Target
3/9/2021NextCureTruist SecuritiesUpgrade
1/15/2021NextCureBank of AmericaDowngrade
8/7/2020NextCureNeedham & Company LLCReiterated Rating
7/16/2020NextCureBenchmarkUpgrade
7/14/2020NextCureBTIG ResearchLower Price Target
7/13/2020NextCureMorgan StanleyDowngrade
7/13/2020NextCureJMP SecuritiesDowngrade
7/13/2020NextCurePiper SandlerLower Price Target
7/13/2020NextCureRoth CapitalDowngrade
7/13/2020NextCureSunTrust BanksDowngrade
12/21/2020Alpine Immune SciencesHC WainwrightInitiated Coverage
8/26/2020Alpine Immune SciencesCowenInitiated Coverage
6/19/2020Alpine Immune SciencesWedbushBoost Price Target
5/26/2020Alpine Immune SciencesLADENBURG THALM/SH SHReiterated Rating
11/13/2019Alpine Immune SciencesPiper Jaffray CompaniesLower Price Target
8/13/2018Alpine Immune SciencesRaymond JamesInitiated Coverage
6/28/2018Alpine Immune SciencesCitigroupInitiated Coverage
1/21/2021iBioCantor FitzgeraldInitiated Coverage
11/18/2020iBioAlliance Global PartnersLower Price Target
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.